Furthermore, a new clinical trial is underway to determine if the GLP-1R signaling pathway influences airway inflammation in obese asthmatics, known as the GLP-1R Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) study. This evidence concerns the gene GLP1R and obesity disorder.